PTEFB inhibiting macrocyclic compounds

US11691986B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Ulrich Lücking · Berlin, DE
• Daniel Hog · Düsseldorf, DE
• Clara Christ · Leverkusen, DE
• Ulrike Sack · Berlin, DE
• Franziska SIEGEL · Cambridge, US
• Philip Lienau · Berlin, DE
• Nicolas Werbeck · Berlin, DE

Key dates

• Filing date: Dec 21, 2021
• Grant date: Jul 4, 2023
• Expiry date: Dec 21, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/08
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).